PinkDx is a diagnostics company focused on gynecologic cancer. The company is developing less invasive, evidence-based diagnostics designed to address important clinical questions, starting with endometrial cancer.

PinkDx’s first indication is endometrial cancer, the fastest-growing gynecologic cancer and one of the few cancers with rising mortality. Black women are about twice as likely as White women to die from the disease. 

PinkDx recently published peer-reviewed evidence in the International Journal of Gynecological Oncology demonstrating that molecular signals associated with endometrial cancer can be detected from a simple vaginal swab. 

Abnormal or postmenopausal bleeding is a common reason women are evaluated for endometrial cancer. About 1.3 million women present with AUB/PMB each year in the U.S.; more than 90% of women with endometrial cancer present with bleeding, yet only about 5% of women evaluated for bleeding will ultimately be diagnosed with endometrial cancer.

PinkDx always starts with unmet clinical needs. The team builds real-world clinical cohorts, applies whole-transcriptome sequencing and machine learning, and continuously creates a highly curated gynecologic cancer data foundation to support product development and clinical insights.

PinkDx’s products are in development and are not currently commercially available. The company is advancing clinical validation of its first diagnostic approach, with independent validation ahead of market launch.